Egfr
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Egfr is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- Integrated network pharmacology, molecular docking, and experimental validation reveal synergistic inhibition of EGFR and PI3K-Akt/JAK2-STAT3 pathways by Esculin and Esculetin to exert anti-colorectal cancer effects. · Toxicol Appl Pharmacol · 2026-08-04
- Comment on "Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colorectal cancer: a network meta-analysis". · Oncologist · 2026-07-25
- Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Post-Progression Therapy When Interpreting Overall Survival” · Journal of Clinical Oncology · 2026-07-20
- Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in TRIPLETE Study · Journal of Clinical Oncology · 2026-07-18
- Advancing Liquid Biopsy: First Clinical Demonstration of Bio-Ferrography for Isolation and Microscopic Characterization of EGFR-Positive Circulating Tumor Cells in Metastatic Cancer. · Cancers (Basel) · 2026-07-15
What the reporting says
It shows up alongside Colorectal Cancer (39), KRAS (17), ctDNA (9), FDA (10), Astrazeneca (8).
Two steps out: AI (through Colorectal Cancer, 39 shared stories on the weaker link); Immunotherapy (through Colorectal Cancer, 39 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 39 shared stories on the weaker link); China (through Colorectal Cancer, 33 shared stories on the weaker link).
Tracked since Dec 3, with coverage on 53 separate days — concentrated in Oncology and Pubmed Targeted.